{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-124510","form_type":"8-K","ticker":"TPST","cik":"0001544227","company_name":"Tempest Therapeutics, Inc.","filed_at":"2023-04-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.338938+00:00","generated_at":"2026-06-16T06:25:37.556625+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Tempest reports positive early Phase 1b/2 data for TPST-1120 in HCC; ORR improved vs control","bullets":["Unconfirmed ORR 30% (12/40) for TPST-1120 arm vs 17.2% (5/29) control, a 74.4% relative improvement.","Confirmed ORR 17.5% (7/40) vs 10.3% (3/29) control, a 69.9% relative improvement.","47.5% (19/40) of TPST-1120 arm patients remain on treatment vs 23.3% (7/30) in control arm.","80% (32/40) in TPST-1120 arm on study vs 50% (15/30) control; safety consistent with control.","Secondary endpoints (DoR, PFS, OS) immature; full data expected at a medical meeting later."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-124510","json":"https://secwatch.observer/filing/0001193125-23-124510.json","markdown":"https://secwatch.observer/filing/0001193125-23-124510.md","text":"https://secwatch.observer/filing/0001193125-23-124510.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1544227/000119312523124510/0001193125-23-124510-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1544227/000119312523124510/d479206d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T06:25:37.556625+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}